NeuroSigma Receives FDA Breakthrough Device Designation for Monarch eTNS System®
February 22, 2022 11:00 ET
|
NeuroSigma, Inc.
LOS ANGELES, Feb. 22, 2022 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a bioelectronic medical device company, today announced FDA Breakthrough Device Designation for its Monarch eTNS System® for...
Ignis Therapeutics Licenses NeuroSigma eTNS Technology for ADHD in a Significant China Licensing Transaction
January 25, 2022 22:30 ET
|
NeuroSigma, Inc.
Ignis obtains rights to develop and commercialize NeuroSigma’s FDA-approved Monarch eTNS System in ChinaInitial launch of Generation 1.0 device followed by Generation 1.5 device, to deploy in mainland...
NeuroSigma Announces Promotion of Dr. Colin Kealey to President
January 11, 2022 11:00 ET
|
NeuroSigma, Inc.
LOS ANGELES, Jan. 11, 2022 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a bioelectronic medical device company, today announced the promotion of Dr. Colin Kealey to President. NeuroSigma is the developer...